Literature DB >> 434600

Impaired alveolar macrophage chemotaxis in patients with acute smoke inhalation.

G B Demarest, L D Hudson, L C Altman.   

Abstract

Pulmonary infection is a leading cause of death in patients with smoke inhalation; however, few studies have evaluated the effects of inhaled smoke on the host defense mechanisms of the lung. In this study we investigated the effects of acute smoke inhalation on the random and chemotactic (stimulated unidirectional) migration of human pulmonary alveolar macrophages. Fiberoptic subsegmental pulmonary lavage was performed in 19 normal subjects (12 nonsmokers and 7 smokers) and 7 patients with smoke inhalation. After quantification of lavaged cell populations, random and chemotactic migration was measured using modified Boyden chambers. Zymosan-activated serum was used as a chemotactic stimulant. Mean +/- SE random migration was 6.2 +/- 0.8 cells per 20 microscopic fields in smoking control subjects, 5.7 +/- 0.7 in nonsmoking control subjects, and 5.2 +/- 0.7 in patients with smoke inhalation. These values are not significantly different. In contrast, the mean directed (chemotactic) migration of pulmonary alveolar macrophages was 26.5 +/- 1.9 in smoking control subjects, 22.7 +/- 3.0 in nonsmoking control subjects, and 11.4 +/- 1.4 in patients with smoke inhalation; the latter response was significantly different from that of the smoking (P less than 0.001) and nonsmoking (P less than 0.025) control subjects and the combined average of the 2 control groups (P less than 0.001. In vitro exposure of pulmonary alveolar macrophages to nontoxic doses of smoke produced similar impairment of chemotaxis. These findings may partially explain the enhanced susceptibility of patients with smoke inhalation to pulmonary infection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434600     DOI: 10.1164/arrd.1979.119.2.279

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Intra-alveolar macrophage numbers in current smokers and non-smokers: a morphometric study of tissue sections.

Authors:  W A Wallace; M Gillooly; D Lamb
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

2.  Management of injury due to smoke inhalation.

Authors:  J Brown
Journal:  J R Soc Med       Date:  1982       Impact factor: 5.344

3.  Functional characteristics of human alveolar macrophages in lung cancer.

Authors:  N Clerici; F Leyva-Cobián; S Reboiras; P Lázaro de Mercado
Journal:  Lung       Date:  1986       Impact factor: 2.584

4.  Changes in alveolar macrophage, monocyte, and neutrophil cell profiles after smoke inhalation injury.

Authors:  B M Riyami; R Tree; J Kinsella; C J Clark; W H Reid; D Campbell; C G Gemmell
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

5.  Functional and metabolic properties of alveolar macrophages in response to the gas phase of tobacco smoke.

Authors:  D B Drath; J M Shorey; G L Huber
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

6.  Smoke inhalation.

Authors: 
Journal:  West J Med       Date:  1981-10

7.  Monocyte responsiveness to chemotactic stimuli is a property of a subpopulation of cells that can respond to multiple chemoattractants.

Authors:  G J Cianciolo; R Snyderman
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

8.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

9.  Surface morphology and function of human pulmonary alveolar macrophages from smokers and non-smokers.

Authors:  M Ando; M Sugimoto; R Nishi; M Suga; S Horio; H Kohrogi; K Shimazu; S Araki
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

Review 10.  Effects of cigarette smoking on metabolic events in the lung.

Authors:  S Kitamura
Journal:  Environ Health Perspect       Date:  1987-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.